The STORY of Xiidra

Patients struggling with dry eye? Help break the cycle of inflammation fast and over time1*

Xiidra in action icon

Xiidra in action

Designed to help break the cycle of dry eye inflammation1

See more
A Vicious cycle the Xiidra difference
Symptoms relief icon

Symptom relief

Xiidra can start to deliver symptom relief in 2 weeks1*

See more
Symptom data Sign data DATA IN CATARACT PATIENTS WITH DRY EYE
Extensive coverage icon

Extensive coverage

Most patients with dry eye are covered nationwide2†

See more
access PATIENT SAVINGS
Resource library icon

Resource library

Find resources to help support your technicians and patients

See more
FOR TECHNICIANS FOR PATIENT SUPPORT FAQs

The exact mechanism of action of Xiidra in dry eye disease is not known.

*Xiidra significantly reduced symptoms of eye dryness at 2 weeks (based on Eye Dryness Score compared to vehicle) in 2 of 4 studies, with improvements observed at 6 and 12 weeks in all 4 studies.1

†Based on data from April 2024. Up to 95% of commercial and 71% of Medicare Part D patients may be covered.2

CONNECT WITH US

CONNECT WITH US

By submitting your information, you consent to receive communications containing information and educational resources about Xiidra, as well as other communications from Bausch + Lomb. By submitting your information, you confirm that you have read and agree with the terms of our Privacy Policy and Legal Notice.

By submitting your information, you consent to receive communications containing information and educational resources about Xiidra, as well as other communications from Bausch + Lomb. By submitting your information, you confirm that you have read and agree with the terms of our Privacy Policy and Legal Notice.

Indication and important safety information

See LessSee Less

Indication

Xiidra® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED).

Important Safety Information

  • Xiidra is contraindicated in patients with known hypersensitivity to lifitegrast or to any of the other ingredients.
  • In clinical trials, the most common adverse reactions reported in 5-25% of patients were instillation site irritation, dysgeusia and reduced visual acuity. Other adverse reactions reported in 1% to 5% of the patients were blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus and sinusitis.
  • To avoid the potential for eye injury or contamination of the solution, patients should not touch the tip of the single-use container to their eye or to any surface.
  • Contact lenses should be removed prior to the administration of Xiidra and may be reinserted 15 minutes following administration.
  • Safety and efficacy in pediatric patients below the age of 17 years have not been established.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Click here for full Prescribing Information for Xiidra.

References

  • Xiidra. Prescribing information. Bausch & Lomb Inc.
  • Data on file. MMIT Portal, April 2024. Bausch & Lomb Inc.

Indication and important safety information

See MoreSee More

Indication

Xiidra® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED).

Important Safety Information

  • Xiidra is contraindicated in patients with known hypersensitivity to lifitegrast or to any of the other ingredients.
  • In clinical trials, the most common adverse reactions reported in 5-25% of patients were instillation site irritation, dysgeusia and reduced